These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33649485)

  • 1. The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24).
    Zhang XL; Yuan SY; Wan G; Yuan MX; Yang GR; Fu HJ; Zhu LX; Zhang JD; Li YL; Gao DY; Cui XL; Wang ZM; Xie RR; Chen YJ
    Sci Rep; 2021 Mar; 11(1):4839. PubMed ID: 33649485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22).
    Zhang XL; Wan G; Yuan MX; Yang GR; Fu HJ; Zhu LX; Xie RR; Lv YJ; Zhang JD; Li YL; Dai QF; Ji Y; Holman RR; Yuan SY;
    Diabetes Ther; 2020 Apr; 11(4):885-903. PubMed ID: 32086768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of cardiovascular risk factor combined anti-platelet therapy and the risk of cerebrovascular events in patients with T2DM in an urban community over 96-months follow-up: The Beijing communities diabetes study 19.
    Zhang XL; Fu HJ; Yang GR; Wan G; Li D; Zhu LX; Xie RR; Lv YJ; Zhang JD; Li YL; Dai QF; Ji Y; Gao DY; Cui XL; Liu DY; Yuan SY; Yuan MX;
    Diabetes Res Clin Pract; 2018 Oct; 144():236-244. PubMed ID: 30218743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Author Correction: The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24).
    Zhang XL; Yuan SY; Wan G; Yuan MX; Yang GR; Fu HJ; Zhu LX; Zhang JD; Li YL; Gao DY; Cui XL; Wang ZM; Xie RR; Chen YJ
    Sci Rep; 2021 May; 11(1):10987. PubMed ID: 34017044
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of the Effect of Nine Consecutive Years' Intensive Management and Number of Times Achieving the Target Control on Endpoint Events in T2DM Patients in Sanlitun Community Health Service Center in Beijing.
    Zhao CM; Cui XL; Wan G; Lu YZ; Niu YQ; Su CY; Cao S; Liang GX; Chen HW; Li J; Lu X; Deng ZY; Yu XH; Yang WX; Li JH; Fan H; Yang MX; Fu Y; Wei SP; He ZN; Zhang XL; Yuan SY
    Int J Endocrinol; 2020; 2020():3646342. PubMed ID: 32148488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
    Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
    Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China.
    Qin Z; Zhou K; Li Y; Cheng W; Wang Z; Wang J; Gao F; Yang L; Xu Y; Wu Y; He H; Zhou Y
    Cardiovasc Diabetol; 2020 Feb; 19(1):23. PubMed ID: 32085772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
    Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
    Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of acarbose in treating elderly patients with diabetes with postprandial hypotension.
    Zhang J; Guo L
    J Investig Med; 2017 Apr; 65(4):772-783. PubMed ID: 28213385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of type 2 diabetes mellitus on recurrent myocardial infarction in China.
    Li W; Li M; Gao C; Wang X; Qi D; Liu J; Jin Q
    Diab Vasc Dis Res; 2016 Nov; 13(6):395-404. PubMed ID: 27390227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study.
    Chen JM; Chang CW; Lin YC; Horng JT; Sheu WH
    J Diabetes Res; 2014; 2014():812628. PubMed ID: 25197673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversion From Pre-Diabetes Mellitus to Normoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in a Chinese Population: A Prospective Cohort Study.
    Liu X; Wu S; Song Q; Wang X
    J Am Heart Assoc; 2021 Feb; 10(3):e019045. PubMed ID: 33496188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
    Bethel MA; Stevens SR; Buse JB; Choi J; Gustavson SM; Iqbal N; Lokhnygina Y; Mentz RJ; Patel RA; Öhman P; Schernthaner G; Lecube A; Hernandez AF; Holman RR
    Circulation; 2020 Apr; 141(17):1360-1370. PubMed ID: 32098501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary.
    Kiss Z; Rokszin G; Abonyi-Tóth Z; Jermendy G; Kempler P; Aradi D; Wittmann I
    Cardiovasc Diabetol; 2018 Jul; 17(1):107. PubMed ID: 30053870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes.
    Chang CW; Liao KM; Chang YT; Wang SH; Chen YC; Wang GC
    J Diabetes Complications; 2019 Feb; 33(2):160-164. PubMed ID: 30381150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
    Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.